What is the 4'-N-benzoylstaurosporine?

4'-N-benzoylstaurosporine is , while it's Molecular Formula is C35H30 N4 O4. Midostaurin is used as a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity. Due to this act which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors. Midostaurin was shown to possess antiproliferative characteristics via inhibition of protein kinase C, kinase insert domain receptor, and c-kit.

What is the CAS number for 4'-N-benzoylstaurosporine?

The CAS number of 4'-N-benzoylstaurosporine is 120685-11-2.

What is 4'-N-benzoylstaurosporine (120685-11-2) used for?

PKC-412 (120685-11-2) is a broad spectrum kinase inhibitor. Inhibited kinases include, but are not limited to; PKA, PKC, S6 Kinase, KDR, PKC, Akt, EGFR, VEGFR, PDGFR, c-kit, and FLT-3. Acute myeloid leukemia related mutant forms of FLT-3 are also inhibited both in vitro and in vivo. PKC-412 has been demonstrated to induce apoptosis and shows broad antiproliferative activity in various tumor cell lines. Cell Permeable

What is the 4'-N-benzoylstaurosporine?

4'-N-benzoylstaurosporine is , while it's Molecular Formula is C35H30 N4 O4. Midostaurin is used as a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity. Due to this act which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors. Midostaurin was shown to possess antiproliferative characteristics via inhibition of protein kinase C, kinase insert domain receptor, and c-kit.

What is the CAS number for 4'-N-benzoylstaurosporine?

The CAS number of 4'-N-benzoylstaurosporine is 120685-11-2.

What is 4'-N-benzoylstaurosporine (120685-11-2) used for?

PKC-412 (120685-11-2) is a broad spectrum kinase inhibitor. Inhibited kinases include, but are not limited to; PKA, PKC, S6 Kinase, KDR, PKC, Akt, EGFR, VEGFR, PDGFR, c-kit, and FLT-3. Acute myeloid leukemia related mutant forms of FLT-3 are also inhibited both in vitro and in vivo. PKC-412 has been demonstrated to induce apoptosis and shows broad antiproliferative activity in various tumor cell lines. Cell Permeable

Product Class

120685-11-2

Product Name：Midostaurin
Molecular Formula：C35H30 N4 O4
Purity：99%
Molecular Weight：570.648

Inquiry

Product Details:

CasNo： 120685-11-2

Molecular Formula： C35H30 N4 O4

Buy High Quality Midostaurin,Best Quality 120685-11-2 Customized Supply

Molecular Formula:C35H30 N4 O4
Molecular Weight:570.648
Melting Point:235-260℃
Boiling Point:°Cat760mmHg
PKA:14.19±0.70(Predicted)
Flash Point:°C
PSA：77.73000
Density:1.46g/cm³
LogP:6.23560

Midostaurin 120685-11-2 Usage

Description

Midostaurin, available under the brand names Rydapt and Tauritmo by Novartis, is a multi-targeted protein kinase inhibitor designed for the treatment of various conditions, including acute myeloid leukemia (AML), myelodysplastic syndrome, and advanced systemic mastocytosis. It is part of a combination therapy for AML, where it is used alongside daunorubicin and cytarabine, both chemotherapy drugs.

Uses

Midostaurin, pronounced MY-doh-STAW-rin, belongs to the class of medications known as kinase inhibitors. It is utilized as an antineoplastic agent to address high-risk AML with specific mutations, as well as aggressive systemic mastocytosis (ASM). In April 2017, the FDA approved midostaurin for the treatment of adult patients with newly diagnosed, FLT3 mutation-positive AML. This approval was granted for use in combination with standard cytarabine and daunorubicin induction, along with cytarabine consolidation. Additionally, midostaurin is indicated for advanced systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, and mast cell leukaemia.

120685-11-2 Relevant articles

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

List of authors. Richard M. Stone, M.D., Sumithra J. Mandrekar, Ph.D., Ben L. Sanford, M.S., Kristina Laumann, B.A., Susan Geyer, Ph.D., Clara D. Bloomfield, M.D., Christian Thiede, M.D., Thomas W. Prior, Ph.D., Konstanze Döhner, M.D., Guido Marcucci, M.D., Francesco Lo-Coco, M.D., Rebecca B. Klisovic, M.D

N Engl J Med 2017; 377:454-464

Patients were randomly assigned to receive standard chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those who were in remission after consolidation therapy entered a maintenance phase in which they received either midostaurin or placebo.

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

Jason Gotlib, M.D., Hanneke C. Kluin-Nelemans, M.D., Ph.D., Tracy I. George, M.D., Cem Akin, M.D., Ph.D., Karl Sotlar, M.D., Olivier Hermine, M.D., Ph.D., Farrukh T. Awan, M.D., Elizabeth Hexner, M.D., Michael J. Mauro, M.D., David W. Sternberg, M.D., Ph.D., Matthieu Villeneuve, M.Sc., Alice Huntsman Labed, Ph.D

N Engl J Med 2016; 374:2530-2541

We conducted an open-label study of oral midostaurin at a dose of 100 mg twice daily in 116 patients, of whom 89 with mastocytosis-related organ damage were eligible for inclusion in the primary efficacy population; 16 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with an associated hematologic neoplasm, and 16 had mast-cell leukemia.

Relevant Products

Apixaban
CAS：503612-47-3
Ixazomib citrate
CAS：1201902-80-8
Vibegron
CAS：1190389-15-1